Keiko Uga
Fujisawa, 2518555, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Novel HDAC6 Inhibitors Increase Tubulin Acetylation and Rescue Axonal Transport of Mitochondria in a Model of Charcot-Marie-Tooth Type 2F.
Journal: ACS chemical neuroscience
Published: December 18, 2019
Design and Synthesis of Conformationally Constrained RORγt Inverse Agonists.
Journal: ChemMedChem
Published: July 12, 2019
Pharmacological evaluation of TAK-828F, a novel orally available RORγt inverse agonist, on murine chronic experimental autoimmune encephalomyelitis model.
Journal: Journal of neuroimmunology
Published: May 29, 2019
Pharmacological effects of TAK-828F: an orally available RORγt inverse agonist, in mouse colitis model and human blood cells of inflammatory bowel disease.
Journal: Inflammation research : official journal of the European Histamine Research Society ... [et al.]
Published: January 10, 2019
Discovery of [ cis-3-({(5 R)-5-[(7-Fluoro-1,1-dimethyl-2,3-dihydro-1 H-inden-5-yl)carbamoyl]-2-methoxy-7,8-dihydro-1,6-naphthyridin-6(5 H)-yl}carbonyl)cyclobutyl]acetic Acid (TAK-828F) as a Potent, Selective, and Orally Available Novel Retinoic Acid Receptor-Related Orphan Receptor γt Inverse Agonist.
Journal: Journal of medicinal chemistry
Published: March 07, 2018
Pharmacological inhibitory profile of TAK-828F, a potent and selective orally available RORγt inverse agonist.
Journal: Biochemical pharmacology
Published: November 14, 2017
Discovery of orally efficacious RORγt inverse agonists, part 1: Identification of novel phenylglycinamides as lead scaffolds.
Journal: Bioorganic & medicinal chemistry
Published: October 11, 2017
Discovery of orally efficacious RORγt inverse agonists. Part 2: Design, synthesis, and biological evaluation of novel tetrahydroisoquinoline derivatives.
Journal: Bioorganic & medicinal chemistry
Published: October 11, 2017
Showing 1-9 of 9
Last Updated: 09/26/2026